In this multicentre randomised trial we have compared a regimen commonly used in Europe, MIP, with the combination GC to test the hypothesis that, in patients with advanced NSCLC, GC would be at least as effective in terms of survival but associated with better quality of life (qol) and fewer hospital admissions. Both regimens were given in a 21-day cycle for up to 4 courses. GC comprised G 1,200mg/m 2 (IV days 1 and 8) and C AUC 5 (IV day 1). MIP comprised M 6mg/m 2 , I 3G/m 2 and P 50mg/m 2 (all IV on day 1). Between February 1999 and August 2001 a total of 422 patients were randomised (GC -212, MIP -210). Patient characteristics: median age 62 years, 70% male, 41% squamous cell, 47%/52% stage IIIb/IV, ECOG PS 0:25%, 1:62%, 2:11%, 3:2%. By October 2001 88%/91% (GC/MIP) patients have completed chemotherapy. Of these 64% GC and 60% MIP received the intended 4 courses. More courses were delayed (11% vs 7%, p=0.009) with GC. Haematological toxicity was the main reason for delay in both arms (60% of delays GC, 50% MIP). GC required fewer in-patient admissions for administration (GC 14% of courses, MIP 89%) and was associated with less nausea, vomiting, alopecia (p<0.0001) and grade 3/4 constipation (p=0.02). Thrombocytopenia grade 3/4 was greater with GC (GC 8% of courses, MIP 3%, p<0.0001), but this was not associated with increased hospital admission or toxic deaths. Overall response rates were similar 37%/ 40% (GC/MIP). However, there was a survival advantage to GC, log-rank p=0.0043 and median survival was GC 10.0 months, MIP 6.5 months. These preliminary results suggest that GC is better tolerated and associated with longer survival than MIP. Qol analyses and updated results will be presented. Patients were randomised to receive standard CHOP therapy (6-8 cycles with at least 2 cycles beyond CR) (n=232) or CHOP x 3 followed by BEAM and ASCT (n=225) providing there had been an objective response to CHOP with no progression at any site, and the bone marrow was morphologically clear of lymphoma after 3 cycles of CHOP. Consolidation radiotherapy was at the discretion of the individual centres. The median age was 48 years (range 16-65) with 278 males and 179 females. The primary endpoint was overall survival (OS) and with a median follow-up of 54 months there is no difference between the two arms (χ 2 =0.15, p=0.7). The actuarial overall survival in the CHOP arm was 54% at 5 years and in the CHOP + BEAM arm was 50 % at 5 years. In the CHOP + BEAM arm only 62% of the randomised patients proceeded to BEAM. Reasons for failure to receive BEAM included: inadequate response to CHOP (40%), persisting marrow disease (10%), patient choice (27%), physician choice reflecting the British Journal of Cancer (2002) 86(Suppl 1), S1 -S12 ª 2002 Cancer Research UK All rights reserved 0007 -0920/02 $25.00 www.bjcancer.com patient's poor general condition (14%) and other (8%). An analysis of progression free survival (PFS) will be presented. This study shows that high dose therapy after only 3 cycles of CHOP is not of overall benefit in poor risk patients. The lack of adequate response to the initial 3 cycles of CHOP in nearly 20% of patients indicates that future trials must address early intensification of therapy.
CT5 MANAGEMENT OF INTERNAL MAMMARY NODES IN SENTINEL NODE BIOPSY
Professor R E Mansel* -Principal Investigator on behalf of the ALMANAC Trialists Group Department of Surgery, University of Wales College of Medicine, Cardiff Introduction: Sentinel Node Biopsy (SNB) is a guided technique for determining axillary lymph node status of patients with breast cancer. Whilst it is hoped that SNB will eliminate unnecessary surgery for two thirds of breast cancer patients who currently receive standard axillary treatment, either axillary clearance or axillary sampling, to date there has been no detailed evaluation of this new technique in the form of a large randomised trial. One of the issues raised by the SNB technique is the management of the internal mammary nodes. The ALMANAC trial (Axillary Lymphatic Mapping Against Axillary Nodal Clearance) is a two staged, multi-centre trial comparing SNB with standard axillary treatment in the management of breast cancer. The first stage, now completed, was an Audit stage where surgeons were evaluated on their ability to successfully perform the technique. The second stage, which is currently ongoing, is comparing SNB with standard axillary treatment in terms of arm and axilla morbidity, health economics and quality of life. The Audit stage data is presented here. Method: In the Audit stage, surgeons performed a sentinel node biopsy before going on to perform their standard axillary procedure, either axillary sampling or axillary clearance. The sentinel node was localised using a combined technique of a radioisotope (Technetium 99m) and blue dye (Patent blue V). In accordance with the ALMANAC protocol the patient was either injected with the radioisotope the day before the operation (40MBq) or on the day of operation (20MBq). This was followed by a static lymphoscintiscan at least three hours from the time of injection. The drainage site was recorded and the number of hot nodes noted. Results: In total 29 surgeons took part in the Audit stage and 803 patients were recruited. Eight patients did not receive a scan due to logistical problems. Data was missing on a further 26 patients leaving 769 cases of analysable data. There were 206 cases (27%) where no drainage site was reported on the scan and 563 cases (73%) where drainage was reported. Axillary drainage was reported in 537(70%) cases and internal mammary drainage in 63(8%). Of the 63 patients, only 22(35%) had lymph nodes removed of which 2 'nodes' proved to be fatty tissue. Only 4 patients had internal mammary nodes that were pathologically positive and in 2 of the patients the axillary nodal status was negative. One patient sustained a pneumothorax and one patient suffered bleeding from the internal mammary artery. Conclusion: Removing the internal mammary nodes remains a difficult routine procedure. Due to the relatively small percentage of patients that have positive internal mammary nodes with negative axillary status (ie have a change in stage), we conclude that routine removal of internal mammary nodes will have a minimal effect on the mortality from breast cancer. Preliminary results in the supportive care setting 725 patients were randomised (364 CT, 361 NoCT). Pre-treatment characteristics: median age 65 years, 74% male, 53% squamous cell, 79% WHO PS 0-1. In the CT group: 65% received the prescribed 3 cycles of chemotherapy (48% with no delays or modification), 28% had grade 3/4 toxicity, mainly haematological (12%), nausea/vomiting (4%) and neutropenic fever (2%), and there were 14 (4%) reported treatment-related deaths. There was a significant survival advantage to the CT group: HR 0.77 (95%CI 0.66-0.91), p=0.0015. Quality of Life (QL) was assessed in a subgroup of 273 patients using patient completed diary cards and the EORTC QLQ-C30 & LC17. There was no evidence of a difference in the pre-defined primary QL endpoint (global health status/QL at 12 weeks) or in any of the secondary endpoints (physical functioning, emotional functioning, fatigue, pain and dyspnoea). Health service costs, estimated in a subgroup of 194 patients using retrospective resource use data collected from hospital records, showed no evidence of a significant offset between the cost of CT and the cost of symptom management.
CT6 THE BIG LUNG TRIAL (BLT): DETERMINING THE VALUE OF CISPLATIN-BASED CHEMOTHERAPY FOR ALL PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC
The preliminary results of this, the largest trial in this setting, confirm the previously reported overall survival benefit with cisplatin-based chemotherapy, as well as the improvement in median survival of approximately 8 weeks. In addition, the sub-studies suggest no evidence of a difference in QL or economic benefit. 
Aim of the Study
The was to determine whether four cycles of chemotherapy given after surgery and before radiotherapy (RT) would improve the outcome for patients with M0-1 medulloblastoma compared with RT alone.
Patients and Methods
Patients aged 3-16 inclusive were randomised to either chemotherapy (vincristine 1.5 mg/m 2 weekly for three weeks, etoposide 100mg/m 2 daily for 3 days and carboplatin 500 mg/m 2 daily for 2 days alternating with cyclophosphamide 1.5 g/m 2 ) followed by craniospinal RT 35 Gy in 21 fractions with a boost of 20 Gy in 12 fractions to the posterior fossa, or RT alone. Results 217 patients were randomised and 179 eligible for analysis (chemotherapy + RT: 90, RT alone: 89). Median age was 7.67 years. Median follow-up was 4.71 years. For all eligible patients overall survival (OS) was 78.9% at 3 years and 71.4% at 5 years. Event free survival (EFS) was 71.5% at 3 years and 66.7% at 5 years. A significant difference in EFS was demonstrated for chemotherapy + RT compared with RT alone. For chemotherapy + RT, EFS was 78.7% at 3 years and 73.4% at 5 years compared with 64.2% at 3 years and 60.0% at 5 years for RT alone (p=0.0419). There was no statistically significant difference in 3-year and 5-year OS between the two arms (82.1% and 76.1% for Chemotherapy + RT, compared with 75.8% and 66.5% for RT alone, p = 0.1662). For patients who had undergone a total resection EFS was significantly better with chemotherapy + RT than with RT alone (p=0.0346), but not for patients who had undergone a less than total resection (p=0.4835).
There was a significantly better EFS (p=0.0184) for patients completing RT within 50 days compared with those taking more than 50 days to complete. Multivariate analysis identified extent of surgical resection (p=0.0398), use of chemotherapy (p=0.0228) and time to complete RT (0.0056) as having a significant impact on EFS. Conclusions This is the first multi-centre, randomised study to demonstrate an improved EFS for patients with medulloblastoma treated with pre-RT chemotherapy compared with RT alone. The importance of avoiding gaps in RT schedules has been confirmed. were not suitable for radical primary therapy due to metastatic disease or co-morbidity. Of the remainder, 50% had CYST and 50% had RRT. After CYST/RRT, 67% / 81% were medically unfit for chemotherapy. Of the 15% eligible for randomisation, 75% declined. The final number of patients randomised was 6. Conclusion: This study demonstrates that population-based cancer research within the NHS is feasible. In the patient group studied there was a higher incidence of co-morbidity than expected and many pts. declined randomisation. This experience is relevant to the development of the new National Cancer Research Network. The difficulty in recruitment in this area supports the recent decision by co-operative groups to collaborate in a international intergroup study to address the issue of adjuvant chemotherapy for bladder cancer.
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